• Biophytis on November 9, 2026, announced the operational launch of its new Shenzhen subsidiary.
• A dedicated local team will lead Chinese preparations for the Phase 3 SARA-31 trial of BIO101 in sarcopenia.
• Asian joint venture partners committed up to USD 20 million over three years, including USD 10 million expected within the first year.
• An initial USD 3 million payment to the venture depends on signing the final licensing agreement following Hong Kong regulatory clearance.
• The company and its founders hold 29% of the joint venture; Asian partners own 71%.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Biophytis SA published the original content used to generate this news brief on November 09, 2026, and is solely responsible for the information contained therein.